TABLE 11.
Results of the selected studies examining checkpoint inhibitors in treating ovarian cancer.
| Name of the study | Year of the study | Phase of the study | Research group | Dose | Results |
|---|---|---|---|---|---|
| NRG GY003 (Zamarin et al., 2020b) | 2020 | II | 100, (treatment 1- nivolumab n = 49, treatment 2 - nivolumab plus ipilimumab n = 51) | Nivolumab 3 mg/kg iv. every 2 weeks or nivolumab 3 mg/kg iv. plus ipilimumab 1 mg/kg iv. every 3 weeks | Treatment 1, treatment 2: OS 21.8, 28.1 months; PFS 2.0, 3.9 months, respectively |
| Lee et al. (Lee et al., 2020) | 2020 | II | 26 (all were given pembrolizumab) | Pembrolizumab 200 mg iv.) every 3 weeks and PLD 40 mg/m2 iv. every 4 weeks | Median PFS—8.1 (1.7–14.7) months and median OS was 18.3 (9.4–31.5) months |
| TPIV200 (Zamarin et al., 2020a) | 2020 | II | 27 | Durvalumab 750 mg intravenously on days 1 and 15 in cycles 1–12, and TPIV200 (500 µg per peptide; Marker, ref IB) admixed with GM-CSF (125 μg; Sargramostim) via three intradermal injections in the upper extremities on day 1 in cycles 1–6 | The median PFS was 2.8 months (2.5–∞), OS was 21 months (13.5–∞) |
| JAVELIN Ovarian 200 (Pujade-Lauraine et al., 2021) | 2021 | III | 566, (avelumab plus PLD n = 188, PLD n = 190, avelumab n = 188) | Avelumab (10 mg/kg iv. every 2 weeks), avelumab plus PLD (40 mg/m2 iv. every 4 weeks), or PLD | Median PFS (3.7 months combination group, 3.5 months in PLD group and 1.9 months in the avelumab group), overall survival (18.4 months vs. 18.2 months vs. 17.4 months) |
| JAVELIN Ovarian 100 (Monk et al., 2021) | 2021 | III | 998, (avelumab n = 332, avelumab combination n = 331, and control n = 335) | Chemotherapy (carboplatin plus paclitaxel) followed by avelumab (10 mg/kg iv. every 2 weeks; avelumab maintenance group); chemotherapy plus avelumab (10 mg/kg iv. every 3 weeks) followed by avelumab maintenance (avelumab combination group); or chemotherapy followed by observation (control group) | Median PFS (16.8 months with avelumab maintenance, 18.1 months with avelumab combination treatment, and 18.2 months with control treatment) |
| NCI-2015–01910 (Konstantinopoulos et al., 2020) | 2021 | II | 70 | Gemcitabine iv. (1,000 mg/m2 during 30 min) on day 1 and day 8 of each 21-day cycle, either alone or in combination with intravenous berzosertib (210 mg/m2 during 1 h) on day 2 and day 9 of each 21-day cycle | Median PFS was 22,9 weeks (17.9–72.0) for gemcitabine plus berzosertib and 14.7 weeks for gemcitabine alone |
| CCR4420 (Papadatos-Pastos et al., 2022) | 2022 | I | 34 | Guadecitabine (45 mg/m2 or 30 mg/m2, administered subcutaneously on days 1–4), with pembrolizumab (200 mg administered iv. starting from cycle 2 onwards) every 3 weeks | PFS achieved for ≥24 weeks |
| CLEE011XUS28T (Coffman et al., 2022) | 2022 | I | 35 | Ribociclib, dosing levels groups: (a) 200 mg, (b) 400 mg, (c) 600 mg | Median PFS - 11.4 months |
| KGOG3046 (Park et al., 2023) | 2023 | II | 23 | Three cycles of durvalumab (1,500 mg) and tremelimumab (75 mg) with NAC, followed by IDS; after surgery, three cycles of durvalumab (1,120 mg) and adjuvant chemotherapy followed by durvalumab maintenance (1,120 mg [total 12 cycles]) were administered | The median PFS was 17.5 months, and the median OS was not reached in the modified ITT population |
iv. - intravenous; PFS, progression-free survival; OS, overall survival; PLD, pegylated liposomal doxorubicin; GM-CSF, granulocyte-macrophage colony-stimulating factor; NAC, neoadjuvant chemotherapy; IDS, interval debulking surgery; ITT, intent to treat.